Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 50 Carcinoma, Non-Small-Cell Lung 39 Carcinoma, Renal Cell 28 Carcinoma, Hepatocellular 18 Neoplasm Metastasis 16 Neoplasms 15 Colorectal Neoplasms 15 Stomach Neoplasms 13 Lung Neoplasms 13 Adenocarcinoma Of Esophagus 11 Squamous Cell Carcinoma of Head and Neck 10 Carcinoma, Transitional Cell 8 Brain Neoplasms 8 Hodgkin Disease 7 Skin Neoplasms 6 Sarcoma 6 Esophageal Neoplasms 6 Clear-cell metastatic renal cell carcinoma 6 Triple Negative Breast Neoplasms 5 Prostatic Neoplasms 5 Pancreatic Neoplasms 5 Kidney Neoplasms 5 Carcinoma, Merkel Cell 5 Uveal Melanoma 4 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Recurrence 4 Neuroendocrine Tumors 4 Nasopharyngeal Carcinoma 4 Mesothelioma 4

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma, Cutaneous Malignant × Nivolumab × Clear all

NCT06743126 2026-05-29

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡